ERBB2 and breast cancer: Although, the effects of TILs on neoadjuvant trastuzumab plus chemotherapy on HER2+ BC patients remain controversial30–32, our data showed that a higher percentage of infiltrating immune cells was present in tumor pCR group compared to pPR group and associated with low RTC post-NACT levels.